$SRPT..$38.98..quite the contrary. The stock is up 20% and has continued to gain more traction throughout the morning. The FDA should approve this drug off of this solid data. If they approved Flibanserin for FSD then they have to (you would think) approve this for kids with Duchenne's Muscular Dystrophy.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.